Two faces of high-molecular-weight kininogen (HK) in angiogenesis: Bradykinin turns it on and cleaved HK (HKa) turns it off

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 4, 2005, Pages 670-676

  Guo, Y L ^a   Colman, R W ^b  

^a University of Southern Mississippi   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Bradykinin; Cell adhesion; Endothelial cells; Kininogen; Kininostatin

Indexed keywords

BRADYKININ; HIGH MOLECULAR WEIGHT KININOGEN; PLASMA KALLIKREIN; ANGIOGENESIS INHIBITOR; PEPTIDE;

ANGIOGENESIS; CELL CYCLE; CELL PROLIFERATION; CELL SURFACE; ENDOTHELIUM CELL; FIBRINOLYSIS; INFLAMMATION; KALLIKREIN KININ SYSTEM; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; THROMBOSIS; ANIMAL; BIOLOGICAL MODEL; CELL ADHESION; CELL MEMBRANE; CHEMISTRY; HUMAN; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

ANGIOGENESIS INHIBITORS; ANIMALS; BRADYKININ; CELL ADHESION; CELL CYCLE; CELL MEMBRANE; CELL PROLIFERATION; HUMANS; KALLIKREIN-KININ SYSTEM; KININOGEN, HIGH-MOLECULAR-WEIGHT; MICE; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; PROTEIN STRUCTURE, TERTIARY;

EID: 23044468258     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01218.x     Document Type: Review

References (71)

1. Weisel JW, Nagaswami C, Woodhead JL, DeLa Cadena RA, Page JD, Colman RW. The shape of high molecular weight kininogen: organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J Biol Chem 1994; 269: 10100-6.
2. DeLa Cadena RA, Colman RW. The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface. Prot Sci 1992; 1: 151-60.
3. Kunapuli SP, DeLa Cadena RA, Colman RW. Deletion mutagenesis of high molecular weight kininogen light chain: identification of two anionic surface binding subdomains. J Biol Chem 1993; 268: 2486-92.
4. Colman RW. Biologic activities of the contact factors in vivo: potentiation of hypotension, inflammation, and fibrinolysis, and inhibition of cell adhesion, angiogenesis, and thrombosis. Thromb Haemost 1999; 82: 1568-77.
5. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-43.
6. van Iwaarden F, deGroot PG, Bouma BN. The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem 1988; 263: 4698-703.
7. Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A, McCrae KR. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 + 3 of the urokinase receptor. J Clin Invest 1997; 100: 1481-7.
8. Hasan AAK, Zisman T, Schmaier AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci USA 1998; 95: 3615-20.
9. Joseph K, Ghebrehiwet B, Kaplan AP. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin Immunol 1999; 92: 246-55.
10. Joseph K, Ghebrehiwet B, Peerschke EI, Reid KB, Kaplan AP. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular 'heads' of C1q (gC1q-R). Proc Natl Acad Sci USA 1996; 93: 8552-7.
11. Mahdi F, Shariat-Madar Z, Todd RF 3rd, Figueroa CD, Schmaier AH. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood 2001; 97: 2342-50.
12. Joseph K, Tholanikunnel BG, Ghebrehiwet B, Kaplan AP. Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thromb Haemost 2004; 91: 61-70.
13. Aguirre Ghiso JA, Alonso DF, Farias EF, Gomez DE, de Kier Joffe EB. Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur J Biochem 1999; 263: 295-304.
14. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001; 86: 346-55.
15. Carroll VA, Binder BR. The role of the plasminogen activation system in cancer. Semin Thromb Hemost 1999; 25: 183-97.
16. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9: 714-24.
17. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-8.
18. Mahdi F, Shariat-Madar Z, Kuo A, Carinato M, Cines DB, Schmaier AH. Mapping the interaction between high molecular weight kininogen and the urokinase plasminogen activator receptor. J Biol Chem 2004; 279: 16621-8.
19. Kleniewski J, Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med 1992; 120: 129-39.
20. Kozik A, Moore RB, Potempa J, Imamura T, Rapala-Kozik M, Travis J. A novel mechanism for bradykinin production at inflammatory sites. Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreins on native and oxidized kininogens. J Biol Chem 1998; 273: 33224-9.
21. Mauron T, Lammle B, Wuillemin WA. High molecular weight kininogen is cleaved by FXIa at three sites. Arg409-Arg410, Lys502-Thr503 and Lys325-Lys326. Thromb Haemost 2000; 83: 709-14.
22. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931.
23. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49: 407-24.
24. Beckner ME. Factors promoting tumor angiogenesis. Cancer Invest 1999; 17: 594-623.
25. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521-4.
26. Folkman J. Tumor angiogenesis. Adv Cancer Res 1974; 19: 331-58.
27. Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 1997; 272: 22924-8.
28. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
29. Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000; 95: 543-50.
30. Zhang JC, Claffey K, Sakthivel R, Darzynkiewicz Z, Shaw DE, Leal J, Wang YC, Lu FM, McCrae KR. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J 2000; 14: 2589-600.
31. Muller-Esterl W, Vohle-Timmermann M, Boos B, Dittman B. Purification and properties of human low molecular weight kininogen. Biochim Biophys Acta 1982; 706: 145-52.
32. Guo YL, Wang S, Cao DJ, Colman RW. Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins. J Cell Biochem 2003; 89: 622-32.
33. Wang S, Hasham MG, Isordia-Salas I, Tsygankov AY, Colman RW, Guo YL. Upregulation of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high-molecular-weight kininogen. Am J Physiol Heart Circ Physiol 2003; 284: H1917-23.
34. Guo YL, Wang S, Colman RW. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 1427-33.
35. Lew DJ, Kornbluth S. Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol 1996; 8: 795-804.
36. Meikrantz W, Gisselbrecht S, Tam SW, Schlegel R. Activation of cyclin A-dependent protein kinases during apoptosis. Proc Natl Acad Sci USA 1994; 91: 3754-8.
37. Porter LA, Singh G, Lee JM. Abundance of cyclin B1 regulates gamma-radiation-induced apoptosis. Blood 2000; 95: 2645-50.
38. Furukawa Y, Iwase S, Terui Y, Kikuchi J, Sakai T, Nakamura M, Kitagawa S, Kitagawa M. Transcriptional activation of the cdc2 gene is associated with Fas-induced apoptosis of human hematopoietic cells. J Biol Chem 1996; 271: 28469-77.
39. Chadebech P, Truchet I, Brichese L, Valette A. Up-regulation of cdc2 protein during paclitaxel-induced apoptosis. Int J Cancer 2000; 87: 779-86.
40. Meikrantz W, Schlegel R. Apoptosis and the cell cycle. J Cell Biochem 1995; 58: 160-74.
41. Vroman L, Adams A. Possible involvement of fibrinogen and proteolysis in surface activation: a study with the recording ellipsometer. Thromb Diath Haemorrh 1967; 18: 510-24.
42. Brash JL, Scott CF, ten Hove P, Wojciechowski P, Colman RW. Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces: role of the contact and fibrinolytic systems. Blood 1988; 71: 932-9.
43. Schmaier AH, Silver L, Adams AL, Fischer GC, Munoz PC, Vroman L, Colman RW. The effect of high molecular weight kininogen on surface-adsorbed fibrinogen. Thromb Res 1984; 33: 51-67.
44. Asakura S, Hurley RW, Skorstengaard K, Ohkubo I, Mosher DF. Inhibition of cell adhesion by high molecular weight kininogen. J Cell Biol 1992; 116: 465-76.
45. Re F, Zanetti A, Sironi M, Polentarutti N, Lanfrancone L, Dejana E, Colotta F. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J Cell Biol 1994; 127: 537-46.
46. Al-Fakhri N, Chavakis T, Schmidt-Woll T, Huang B, Cherian SM, Bobryshev YV, Lord RS, Katz N, Preissner KT. Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. Biol Chem 2003; 384: 423-35.
47. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 1996; 134: 793-9.
48. Sajid M, Stouffet GA. The role of alpha (v) beta 3 integrins in vascular healing. Thromb Haemost 2000; 87: 187-93.
49. Chavakis T, Kanse SM, Lupu F, Hammes HP, Muller-Esterl W, Pixley RA, Colman RW, Preissner KT. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin-and urokinase receptor-dependent interactions. Blood 2000; 96: 514-22.
50. Kjoller L, Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol 2001; 152: 1145-57.
51. Ciambrone GJ, McKeown-Longo PJ. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem 1992; 267: 13617-22.
52. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem 2000; 275: 21785-8.
53. Cao DJ, Guo YL, Colman RW. Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Circ Res 2004; 94: 1227-34.
54. Sheng N, Fairbanks MB, Heinrikson RL, Canziani G, Chaiken M, Mosser DM, Zhang H, Colman RW. Cleaved high molecular weight kininogen binds directly to the integrin CD11b/CD18 (Mac-1) and blocks adhesion to fibrinogen and ICAM-1. Blood 2000; 95: 3788-95.
55. Zhang JC, Donate F, Qi X, Ziats NP, Juarez JC, Mazar AP, Pang YP, McCrae KR. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci USA 2002; 99: 12224-9.
56. Renne T, Dedio J, David G, Muller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J Biol Chem 2000; 275: 33688-96.
57. Fernando LP, Fernando AN, Joseph K, Kaplan AP. Assessment of the role of heparan sulfate in high molecular weight kininogen binding to human umbilical vein endothelial cells. J Thromb Haemost 2003; 1: 2444-9.
58. Maeshima Y, Manfredi M, Reimer C, Holthaus KA, Hopfer H, Chandamuri BR, Kharbanda S, Kalluri R. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 2001; 276: 15240-8.
59. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, Sonenberg N, Hynes RO, Kalluri R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002; 295: 140-3.
60. Colman RW, Pixley RA, Sainz I, Song JS, Isordia-Salas I, Muhamed SN, Powell JA Jr, Mousa SA. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J Thromb Haemost 2003; 1: 164-70.
61. Song JS, Sainz IM, Cosenza SC, Isordia-Salas I, Bior A, Bradford HN, Guo YL, Pixley RA, Reddy EP, Colman RW. Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood 2004; 104: 2065-72.
62. Espinola RG, Uknis A, Sainz IM, Isordia-Salas I, Pixley RA, DeLa Cadena R, Long W, Agelan A, Gaughan J, Adam A, Colman RW. A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis. Am J Pathol 2004; 165: 969-76.
63. Hayashi I, Amano H, Yoshida S, Kamata K, Kamata M, Inukai M, Fujita T, Kumagai Y, Furudate S, Majima M. Suppressed angiogenesis in kininogen- deficiencies. Lab Invest 2002; 82: 871-80.
64. Morbidelli L, Parenti A, Giovannelli L, Granger HJ, Ledda F, Ziehe M. B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF-2 effects. Br J Pharmacol 1998; 124: 1286-92.
65. Parenti A, Morbidelli L, Ledda F, Granger HJ, Ziehe M. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J 2001; 15: 1487-9.
66. Knox AJ, Corbett L, Stocks J, Holland E, Zhu YM, Pang L. Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism. FASEB J 2001; 15: 2480-8.
67. Ishihara K, Kamata M, Hayashi I, Yamashina S, Majima M. Roles of bradykinin in vascular permeability and angiogenesis in solid tumor. Int Immunopharmacol 2002; 2: 499-509.
68. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3: 319-28.
69. Seegers HC, Avery PS, McWilliams DF, Haywood L, Walsh DA. Combined effect of bradykinin B2 and neurokinin-1 receptor activation on endothelial cell proliferation in acute synovitis. FASEB J 2004; 18: 762-4.
70. Thuringer D, Maulon L, Frelin C. Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem 2002; 277: 2028-32.
71. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 2001; 89: 678-83.